Clinical Research Papers:

LncRNAs act as prognostic and diagnostic biomarkers in renal cell carcinoma: a systematic review and meta-analysis

Jianwen Chen, Yalei Chen, Liangyou Gu, Xintao Li, Yu Gao, Xiangjun Lyu, Luyao Chen, Guoxiong Luo, Lei Wang, Yongpeng Xie, Junyao Duan, Cheng Peng and Xin Ma _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:74325-74336. https://doi.org/10.18632/oncotarget.11101

Metrics: PDF 2262 views  |   HTML 2859 views  |   ?  


Jianwen Chen1,*, Yalei Chen2,*, Liangyou Gu1, Xintao Li1, Yu Gao1, Xiangjun Lyu1, Luyao Chen1, Guoxiong Luo1, Lei Wang1, Yongpeng Xie1, Junyao Duan1, Cheng Peng1 and Xin Ma1

1 Department of Urology/State Key Laboratory of Kidney Diseases, Chinese People’s Liberation Army General Hospital, Beijing, China

2 Department of Cardiology, Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China

* These authors have contributed equally to this work

Correspondence to:

Xin Ma, email:

Keywords: lncRNA; renal cell carcinoma; clinicopathology; diagnosis; prognosis

Received: April 03, 2016 Accepted: July 19, 2016 Published: August 05, 2016


We conducted a systematic review and meta-analysis to investigate the clinical values, including clinicopathology, prognosis, and diagnosis of different long non-coding RNAs (lncRNAs) in renal cell carcinoma (RCC). A total of 14 eligible studies, including 10 on clinicopathological features, 11 on prognosis, and 3 on diagnosis were identified. Results revealed that metastasis-associated lung adenocarcinoma transcript 1(MALAT1) expression was associated with tumor stage (odds ratio [OR], 3.46; 95% confidence interval [CI], 1.63-7.36; p=0.001). The high expression of MALAT1 could be considered a biomarker of the early detection of lymph node metastasis and predictor of poor survival in RCC patients, who likely manifested short overall survival (OS; hazard ratio [HR], 2.97; 95% CI, 1.68-5.28; p<0.001). For diagnostic value, the pooled result showed that lncRNA maintained a sensitivity of 0.89 and specificity of 0.91 in RCC diagnosis, The area under the curve of 0.94 (95% CI, 0.92-0.96) for lncRNA in RCC diagnosis also indicated a significant advantage over other biomarkers. Our systematic review and meta-analysis demonstrated that lncRNAs could be considered biomarkers to detect lymph node metastasis and distant metastasis in early stages. LncRNAs could function as potential prognostic markers in RCC. LncRNAs could also display high accuracy for RCC diagnosis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11101